The Bayer serum IIER-2/neu oncoprotein test is available on Bayer’s automated immunoassay platform, the ADVIA Centaur® immunoassay system. The blood test measures circulating levels of the IIER-2/neu oncoprotein to help oncologists treat patients with metastatic breast cancer. The test was cleared for use on the ADVIA Centaur system by the US Food and Drug Administration earlier this year.
    Studies have shown that in certain breast cancer patients, persistently rising IIER-2/neu values may be associated with aggressive cancer and poor response to therapy, while decreasing IIER 2/neu levels may be indicative of effective therapy. Traditional IIER-2/neu testing is generally limited to tissue from primary breast cancer and does not provide information regarding the IIER-2/neu status in women with recurrent metastatic breast cancer. The introduction of IIER-2/neu testing on an automated platform using a serum sample offers a less invasive diagnostic tool and provides a current assessment of a woman’s IIER-2/neu status over the course of the disease.
Bayer HealthCare Diagnostics Division
www.CLPmag.com